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Abstract
We sought to identify cognitive phenotypes for family/genetic studies of successful cognitive
aging (SCA; maintaining intact cognitive functioning while living to late old age).We
administered a battery of neuropsychological tests to nondemented nonagenarians (n = 65; mean
age = 93.4±3.0) and their offspring (n = 188; mean age = 66.4±5.0) from the Central Valley of
Costa Rica. After covarying for age, gender, and years of education, as necessary, heritability was
calculated for cognitive functions at three pre-defined levels of complexity: specific
neuropsychological functions (e.g., delayed recall, sequencing), three higher level cognitive
domains (memory, executive functions, attention), and an overall neuropsychological summary.
The highest heritability was for delayed recall (h2 = 0.74, se = 0.14, p < 0.0001) but significant
heritabilities involving memory were also observed for immediate recall (h2 = 0.50), memory as a
cognitive domain (h2 = 0.53), and the overall neuropsychological summary (h2 = 0.42).
Heritabilities for sequencing (h2 = 0.42), fluency (h2 = 0.39), abstraction (h2 = 0.36), and the
executive functions cognitive domain (h2 = 0.35) were also significant. In contrast, the attention
domain and memory recognition were not significantly heritable in these families. Among the
heritable specific cognitive functions, a strong pleiotropic effect (i.e., evidence that these may be
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influenced by the same gene or set of genes) for delayed and immediate recall was identified
(bivariate statistic = 0.934, p < 0.0001) and more modest but significant effects were found for
four additional bivariate relationships. The results support the heritability of good cognitive
function in old age and the utilization of several levels of phenotypes, and they suggest that
several measures involving memory may be especially useful for family/genetic studies of SCA.
Keywords
Family studies; hispanic population; neuropsychological phenotype; oldest-old; successful
cognitive aging
INTRODUCTION
Several genes have been identified with variants that either cause or increase the risk for
Alzheimer’s disease (AD) [1], and there has been recent notable progress in the search for
others [2–4]. The genetics of successful cognitive aging (SCA; maintaining intact cognitive
functioning while living to late old age) has been studied much less. Genes with variants that
protect against late life cognitive impairment may overlap to some extent with genes with
alleles that increase risk. At present, the apolipoprotein E (APOE) gene provides the only
strongly confirmed example of this [5, 6], where the APOE-ε4 allele increases risk and the
APOE-ε2 allele protects against dementia. Alternatively, there may be genes associated with
late life cognition that do not possess minor alleles increasing both risk and protection.
Genes with infrequent minor protective allele(s)would not likely be identified in current
research focused on dementia if there were not also an allele associated with dementia, such
as APOE-ε4 [7]. In view of the multidimensionality of both cognitive function and
longevity, simply living to a very late age without dementia may be too genetically complex
to meaningfully empower such a search [7–10]. Delineating phenotypes for SCA could
facilitate the search for relevant genes that hold the potential to reveal much about the
physiology of resilient late-life cognitive function; such knowledge would be harder to glean
from studies of dementia alone.
A large, consistent literature, based primarily on studies of twins and families rather than
molecular genetics per se, already demonstrates the important influence of genetic factors on
normal cognitive function in early life [11]. While not so well established, twin study
evidence suggests that genetic factors are important for late life cognitive function too [9,
12], and not subsumed simply by those directly associated with risk of dementia [13]. Also,
family studies of SCA have reported that the first degree relatives of SCA probands have a
reduced risk for dementia [7, 14, 15], consistent with the presence of familial/genetic
underpinnings for SCA.
If the genetic basis of SCA involves multiple genes [8–10], identifying cognitive phenotypes
associated with SCA will facilitate genetic studies. Such phenotypes may pertain to different
levels of cognitive complexity, reflecting genetic factors affecting specific or broader
cognitive functions. Results from genetic epidemiological studies suggest that some genes
may be “generalist” in their cognitive effects, i.e., they may have broad effects on cognitive
function [11, 16]. Such genes might, for example, influence a core physiological (e.g.,
synaptic plasticity), physical (e.g., neural density), or other process that, in turn, may lead to
a broad or cascading effect on a range of cognitive functions [16]. Under a generalist gene
hypothesis, such genes would be best detectable by characterizing an overall measure of
cognitive functioning in individuals, or by having associated deficits in a wide variety of
cognitive functions rather than a deficit in one specific area. This approach argues for
determining the heritability of a summarizing measure of neuropsychological function [16].
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Alternatively, such genes may influence a specific cognitive function or only a set of closely
related functions. Twin and family data suggest that specific components of memory, such
as delayed recall, have a high heritability, while other cognitive functions may have a much
lower heritability, depending on the sample characteristics [9, 10, 17, 18]. Recently,
molecular genetic studies have reported on polymorphisms that have effects on specific
cognitive functions. For example, common variants of the Kibra (WWC1) and the
Cholesteryl Ester Transfer Protein (CETP) genes have been found to be associated with
episodic memory and not with other cognitive functions [19–23].
To evaluate the heritability of cognitive function in SCA at several different levels of
cognitive complexity, we examined SCA probands and their offspring ascertained in the
Central Valley of Costa Rica (CVCR). The CVCR population has many features that make it
attractive for genetic studies. While the CVCR population used for these analyses is
considered an admixed population, this admixture occurred during the time of the
colonialization of Costa Rica in the sixteenth century [24]. Since that time, the people of the
Central Valley region (two thirds of Costa Rica’s 3.5 + million people live in the CVCR)
have remained demographically isolated, with reduced genetic heterogeneity, observed
especially among the very elderly of the region and advantageous for genetic studies. A
recent genetic study of 426 unrelated CVCR individuals with a familial history of mental
disorder provided no evidence for population substructure [25]. Other advantageous features
of the CVCR population include a high level of cultural homogeneity which helps to limit
environmental disparities, close knit families, and a small geographic size, typically making
sibship members readily accessible for study [26, 27].
MATERIALS AND METHODS
All participants were recruited in accordance with the principles of the Helsinki Declaration
and approval of the Institutional Review Boards of the University of Costa Rica and Mount
Sinai Medical Center. All individuals signed informed consent prior to their participation.
SCA probands
SCA probands with at least one living, available offspring were ascertained through referrals
to the study geriatric physician (DV) from a network of cooperating physicians associated
with the Costa Rican Association of Geriatricians. Probands and their spouses were required
to be native to the CVCR. Eligible probands were required to be at least 90 years of age, as
verified by the cédula, the national identity card that every Costa Rican citizen possesses and
which includes a picture ID and the individual’s date and place of birth. The age 90
threshold was chosen because prior studies indicate the relatives of nondemented 90 + year
olds maintain intact cognitive function better even than relatives of nondemented elderly
who are still in their late 80s [7].
Probands received a clinical dementia evaluation using the Clinical Dementia Rating scale
(CDR) [28] and the Mini-Mental State Examination [29] and a medical exam by a
geriatrician. In the CDR, clinical information is collected from both an informant and the
subject. The subject’s memory, judgment, orientation, home and hobbies, community
affairs, and personal care are assessed. Probands were required to have a CDR score of zero,
indicating no dementia or recent decline in cognition or functioning. Additionally, the
physician (DV) with expertise in dementia assessed all probands and ensured their cognitive
normal status. We deliberately did not include neuropsychological testing performance as a
criterion for proband eligibility to avoid circularity in our study since the dependent
variables—cognitive functions—under study were derived from these test scores.
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Offspring of SCA probands
We recruited the 60+ year old offspring of SCA probands for this study. Contact with a
given offspring was made through the proband. While the proband’s intact cognitive status
was a determinant for eligibility, this was not the case for the offspring; the presence of
dementia, for example, was not an exclusion, although to date such cases have been absent
in our sample.
Neuropsychological assessment
The neuropsychological test battery included Spanish translations of the Uniform Data Set
(UDS) battery and supplemental tests used to characterize cognitive functions. Validity of
this battery is supported by our overall similar results, after taking into account the
difference in years of education, for the Spanish and English versions of the test battery in
respective samples of nonagenarians from Puerto Rico and New York [30]. Based on earlier
factor analyses of neuropsychological batteries, we have conducted in elderly samples [30–
32] as well as factor analyses from other researchers [33, 34], we defined phenotypes at
three levels of cognitive complexity. The lowest level focused on specific
neuropsychological functions (e.g., delayed recall, sequencing). The middle level focused on
three key cognitive domains: memory, executive functions, and attention. The highest level
was an overall summary score of cognitive functioning. The tests were administered at the
homes of the subjects by team psychologists (LV, KC) who were trained and certified by
JCB and who, along with JMS, MSB, and MS, provided ongoing supervision. The specific
functions and the associated tests administered were:
I. Memory domain
i. Immediate Recall.Word List Memory [35]: a free recall memory test that assesses
learning ability for new verbal information. Three trials of a 10-item word list are
presented with varying orders on each trial. Immediately following each trial, the
subject is asked to recall as many as possible. The sum of the correct words over
the three trials is the measure. Logical Memory: this is a subtest of the Wechsler
Memory Scale-III [36] in which the tester reads a story aloud and subjects are
asked to immediately recall it. The number of 25 specific details mentioned is the
score. This story is also used to measure delayed recall and recognition.
ii. Delayed Recall. Word List: after a 15 minute delay (filled with other tests in the
battery), subjects are asked to recall the 10 words of the Word List Memory test.
Logical Memory: after a 25–30 minute delay, subjects are asked to recall the story
from the Logical Memory test.
iii. Recognition. Word List: The 10 words in the Word List Memory test are presented
along with 10 distracter words. The score equals the number of correctly
recognized (Rec-yes) plus the number of distracter words correctly identified (Rec-
no). Since this had a substantially skewed distribution, a logarithmic transformation
was applied, −log (21-score), which yielded an approximately normal distribution.
II. Executive functions domain
i. Sequencing. Trail Making Tests: these tests measure timed attention, mental
flexibility, and sequencing. In Part A the subject is asked to connect randomly
positioned numbers in sequence with a pencil. In Part B subjects are asked to
connect consecutive numbers and letters in alternating order [37]. The score used
for each test is the time (seconds) to completion.
ii. Abstraction. Similarities: this is a subtest from the Wechsler Adult Intelligence
Scale-Revised [38] measuring abstract thinking by asking the subject to state how
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pairs of words (e.g., egg/seed) are alike. The number of correctly answered pairs is
the single measure from this test.
iii. Fluency. Controlled Oral Word Association Test: in three one-minute trials, this
test of phonemic fluency assesses the ability to name as many words as possible
with three different letters. The English version uses F, A, and S [39] but, as the
letters “S” and “Z” always sound like an “S” in Spanish, this letter has been
changed to “N”. The single measure is the sum of words in all three trials. Category
Fluency: Subjects are asked to generate exemplars of animals, foods, and clothing;
60 seconds are allowed for each category. The score is the sum of the exemplars of
the different categories [40].
III. Attention domain
i. Visual/Spatial Attention. Target Cancellation Tests [41]: these tests assess
vigilance and speeded attention, requiring an organized, planned search. Two forms
are used here, the Letters test requires the subject to identify the letters ‘TMX’ in
an array of letter triads; the Shapes test requires the subject to identify diamonds
among other geometric figures. Target stimuli are interspersed with distracter items
on a sheet of 8.5-by-11 paper in a generally random format. The numbers of targets
identified in two minutes on each task are the two measures.
Figure 1 shows the three cognitive levels of phenotypes examined and the associated tests.
These phenotypes were chosen to facilitate replication in independent samples. Each
specific neuropsychological function in the lowest level was estimated by the sums of z-
scores of sets of one or more neuropsychological measures. For example, z score
transformations were calculated for both the word list test and the logical memory test and
the two scores were then summed to derive a score for the neuropsychological function,
immediate recall. For the middle level, the memory and executive functions were each
estimated by a sum of z-scores of a set of three neuropsychological functions from the level
below. For the cognitive domain of attention, the two versions of the Target Cancellation
Task, letters and shapes, were used, but they were not considered sufficiently different to be
treated as distinct neuropsychological functions at the lowest level. Moreover, the
distribution of the summed z-scores of these two measures was highly kurtotic. The sum of
z-scores of these two measures was log- transformed, yielding an estimate of attention that
was approximately normally distributed. Finally, the overall neuropsychological summary
was the phenotype estimated by the sum of z-scores of the three cognitive domains.
Statistical analysis
Heritability (h2r) estimates were obtained for each cognitive function phenotype using the
variance component methodology implemented in the SOLAR v.2.1.2 linkage analysis
package [42]. Although the variance component method is quite robust to violations of
multivariate normality within pedigrees [43, 44], the distribution of values for each
phenotype was analyzed to assess large departures. All phenotypes were approximately
normally distributed with no significant outliers identified. Since controlling for the effects
of a known covariate is important for obtaining an accurate estimate of heritability, three
factors (age, gender, and years of education) likely to affect these phenotypes were screened
for significance as covariates using SOLAR. Although the APOE genotype was determined
for most of the subjects (n = 246), the allele frequencies for ε4 and ε2 were sufficiently low
(6.8% and 2%, respectively) that APOE was not screened as a potential covariate because it
would be unlikely to account sufficient variation in the entire sample. Only those factors that
showed significant (p < 0.05) associations were retained in the heritability analysis of that
phenotype. For pairs of domains and pairs of phenotypes with significant heritability,
bivariate genetic (ρG) and environmental (ρE) correlations were also computed using
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SOLAR [45, 46]. The genetic correlation between two phenotypes is the component of the
overall correlation that is due to pleiotropy (i.e., single genetic effects influencing multiple
phenotypes), which is obtained from kinship information in the pedigree. The environmental
correlation is the component of the correlation due to environmental factors that influence
both measures, which is obtained from the individual-specific error.
RESULTS
The upper portion of Table 1 presents the demographic characteristics of the SCA probands,
their offspring, and the combined group of relatives. The lower portion of Table I presents
the scores for each of the cognitive phenotypes. To reflect the organization of the
phenotypes, as shown in Fig. 1, we have indented the three cognitive domains in Table I,
and further indented the specific neuropsychological phenotypes investigated.
We assessed 84 eligible enrolled SCA probands and 188 of their offspring. Of these, 19
probands had incomplete neuropsychological test data, so they could not be included in the
heritability analysis, but their 53 offspring were included, for a total of 253 family members.
In a subsidiary analysis, we limited the heritability analysis to only those families that
included a proband without missing data and the results were very similar (data not shown).
Heritability results and their significance levels for each phenotype are shown in Table 2.
The overall neuropsychological summary and two of the three cognitive domains (memory
and executive functions) were found to be significantly heritable, but not the attention
domain. Within the memory domain, delayed and immediate recall were significantly
heritable, but not recognition. The three associated specific neuropsychological functions
associated with executive functions were also significantly heritable.
The last three columns of Table II present the significance levels of the three potential
covariates (employed in the heritability analysis only if p < 0.05). For every phenotype,
more years of education was found to be highly significantly associated with better
neuropsychological functions, domains, and the overall summary score. Also, later age was
significantly associated with better executive functions performance and the overall
neuropsychological summary score, but was not associated with the memory phenotypes or
attention. Gender was a significant covariate only for the memory domain and the
immediate and delayed recall phenotypes, where the performance scores for women were
better than for men (data not shown).
In a subsidiary analysis, we excluded probands and calculated heritability among only the
offspring. These results, shown in Table 3, were generally similar to those observed with the
SCA probands included.
The significant bivariate correlations, shown in Table 4 a & b, are estimates of the strength
of the components of the observed correlations between each pair of heritable phenotypes
that can be attributable to genetic (ρG; below the diagonal) and environmental (ρE; above the
diagonal) factors. A larger ρG is generally indicative of increased evidence for shared genes
(pleiotropy).We also present significance corrected for multiple testing using the Bonferroni
method, which may be unduly conservative due to the correlations among many of the
neuropsychological functions. A very strong genetic correlation was observed between
immediate and delayed recall. Immediate recall was also correlated with sequencing and
abstraction, as were the latter two phenotypes with each other. There was also a significant
correlation between delayed recall and abstraction. We additionally examined environmental
correlations and found that fluency, which was not genetically correlated with any other
phenotype, was correlated with all the other specific neuropsychological functions in
contrast to all the other separate pair-wise combinations of phenotypes. No significant
Greenwood et al. Page 6
J Alzheimers Dis. Author manuscript; available in PMC 2012 December 19.
$watermark-text
$watermark-text
$watermark-text
genetic correlations were observed between the two heritable cognitive domains, but a
significant environmental correlation between the memory and executive domains was
observed.
DISCUSSION
Genetic factors, even beyond their association with dementias such as AD [13], likely
underlie the variability in cognitive function across individuals as they move into late life
[47]. SCA, in particular, has been repeatedly found to be a familial characteristic and
probably has genetic underpinnings [7, 14, 15]. Delineation of heritable SCA cognitive
phenotypes may be useful for the identification of its genetic determinants. In a CVCR
ascertained sample of SCA probands and their offspring, we considered three levels of
phenotypic complexity. In support of our multi-level approach to cognitive phenotypes in
late life, within each of the three levels of phenotypes there were significant heritabilities.
Nonetheless, we note that the strongest heritabilities were mostly found at the most specific
level of function and these were reduced higher levels. Although we cannot rule out the
possibility that shared familial environmental influences have affected these heritability
calculations, our results suggest that most of cognitive phenotypes examined have good
potential to be useful in the search for genes associated with SCA.
Two specific functions related to memory, delayed recall and immediate recall, had the
highest heritabities and, among the three cognitive domains, memory was highest,
suggesting that certain memory-related phenotypes may be particularly valuable in the
search for genetic determinants associated with SCA. On the other hand, recognition,
another cognitive function related to memory, and the attention domain were not found to be
heritable in this sample and hence are probably less useful for genetic studies.
The bivariate analyses we conducted that assessed the genetic and environmental
associations between pairs of phenotypes within the same level of phenotypic complexity
indicated several significant environmental and genetic inter-correlations, especially the
genetic inter-correlation between delayed and immediate recall (ρG = 0.96). The genetic
correlations offer opportunities to explore the potential common underlying genetic and
neurobiologic substrates of these phenotypic measures. These will be possible as the sample
grows and genetic data become available. The presence of significant inter-domain genetic
associations as well as intra-domain associations is consistent with the possibility of
pleiotropic effects, but lack of significance for many pair-wise associations argues against
exclusively generalist genes.
That delayed recall showed the highest heritability is consistent with other studies that
assessed heritability in aged twin and family samples [48]. In particular, our results showed
some similarities to a study of families with AD probands ascertained in the Dominican
Republic and Puerto Rico where the heritability for delayed recall in their full family sample
was 60%, whereas heritability for recognition, while significant, was less high (41%) [17].
In our study, heritability for delayed recall was even somewhat higher while recognition was
low and not significant when the probands were included and showed a modest significant
heritability when offspring alone were included. The reason for the discrepancy in the
results with recognition may depend on our use of a logarithmic transformation. In addition,
two distinguishing characteristics of our sample was that no subjects had dementia and all
the subjects either were SCA probands—a relatively rare, desirable condition associated
with familial/genetic protection of cognitive functions [7, 14, 15]—or their offspring.
Beyond its strong association with AD and other dementias, investigations of the APOE-ε4
allele in cognitively healthy elderly have collectively found modest effects on overall
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neuropsychological functioning and on memory, but smaller or no effects on other specific
cognitive functions [49]. Although age-associated memory impairments may indicate a
degenerative process, a decremental impairment in attention or executive function may be a
normal characteristic of aging [50]. Thus, the stronger impact of the APOE ε4 allele on
memory over other cognitive domains may speak to a stronger relationship with dementia
risk than an influence on normal cognitive function [51]. Since as discussed above, it is
unlikely that the relatively low variation of APOE alleles had substantial effect on the
documented heritabilities, the findings support contributions from genes other than APOE
on memory and other cognitive functions. Such genes need not be associated with AD
pathophysiology per se, but may also be associated with maintaining good cognitive
functioning even in the face of AD-related processes such as plaque formation. For example,
the cognitive reserve theory relates such maintenance to a high level of prior cognitive
performance [52, 53]. Protective genes may help explain reports of high levels of AD
neuropathology found in brains of some very long-lived cognitively intact individuals [53–
55].
The covariates were incorporated in the heritability analyses to remove the confounding
effects of demographic variables on cognition. The absence of a strong covariate effect of
age is surprising in view of the well established association of age with memory in samples
from general populations [56]. A recent study from our group developed norms for very
elderly nondemented subjects from the New York City area on 14 neuropsychological tests
on which most tests in this study were based. For the tests of memory, the pattern of
significances for age was the similar to that of the present study, except that one of two
recognition tests was significant. Also, in a sample of nondemented nonagenarians Puerto
Ricans, none of the neuropsychological tests were significantly associated with age or
gender, but most were associated with education [30]. Although the age ranges were
restricted in those previous studies to cognitively intact 85+ and 90+ year olds, respectively,
including only SCA probands and their offspring in the present study may have reduced the
association of age with memory by reducing dementia-associated effects.
There are methodological considerations and limitations in this study that require attention.
First, since the sample was restricted to very elderly nondemented probands and their
offspring, these heritabilities may not be characteristic of the general population. Indeed,
some twin studies reflecting the more general population of nondemented elderly have
found somewhat different patterns of heritability [9]. Second, our neuropsychological
battery included three important cognitive domains, but the number of phenotypes in each
domain (especially for attention) and the number of tests in phenotypes were limited. Third,
the variation in APOE genotypes was not sufficiently large to distinguish its heritability
from other sources with this sample size. Finally, we note that we did not have systematic
information on medical co-morbidities and treatments and thus could not include these as
potential covariates that might have affected cognitive function.
Our results suggest that cognitive phenotypes at several levels, focusing especially on
memory (overall neuropsychological summary, memory, and delayed recall) have
substantial heritability that may prove useful for identifying genes associated with SCA.
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Fig. 1.
Three levels of neuropsychological phenotypes examined and the specific tests used. Note:
Two versions of the target cancellation test (shapes and letters) were used to establish the
attention domain score, middle level. However, these two tests were deemed insufficiently
distinct to be treated separately, i.e., as individual neuropsychological functions at the
bottom level.
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Table 1
The demographic, neuropsychological phenotype characteristics of SCA probands and their offspring
Characteristic SCA probands Offspring of
SCA probands
Total
Demographics
    N       65       188       253
    Age y (SD)   93.4 (3.0)   66.4 (5.0)   73.3 (12.7)
    Female n (%)     43 (66)     122 (65)     156 (65)
    Education y (SD)    3.6 (2.9)     8.6 (5.1)     7.3 (5.1)
Cognitive phenotypes
 Mean (SD)   Mean (SD)  Mean (SD)
Neuropsychological summary* −0.20 (2.52)   0.09 (2.30)   0.00 (2.37)
Memory* −0.16 (2.66)   0.03 (2.54) −0.04 (2.59)
    Immediate Recall* −0.16 (1.74)   0.05 (1.71) −0.02 (1.73)
    Delayed Recall* −0.09 (1.76)   0.02 (1.75) −0.01 (1.75)
    Recognition (Word list recognition)† 15.2 (3.6) 18.1 (2.1) 17.3 (2.87)
Executive functions* −0.22 (2.14)   0.07 (2.37) −0.02 (2.32)
    Sequencing* −0.19 (1.52)   0.01 (1.74) −0.04 (1.70)
    Fluency* −0.16 (1.67)   0.07 (1.81)   0.00 (1.78)
    Abstraction (Similarities)†   7.9 (5.2) 14.1 (6.1) 12.4 (6.5)
Attention* −0.42 (1.00)   0.05 (0.95)   0.02 (0.96)
*
Z scores,
†
Raw scores.
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